A feature stemming from its molecular design that separates NX‐5948 from other BTK‐targeted proteolysis‐targeting chimeras (PROTACs) is its ability to cross the blood–brain barrier and degrade BTK intracranially, translating to preclinical efficacy in CNS lymphomas [40]. The gene discussed is BTK; the disease is primary central nervous system lymphoma.